Inflammatory Disease News and Research

RSS

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients.

11 Jun 2014

Study examines how food additive MSG contributes to obesity and liver disease

The commonly used food additive monosodium glutamate (MSG) has been linked to obesity and disorders associated with the metabolic syndrome including progressive liver disease.

28 May 2014

Study identifies role of additive monosodium glutamate in obesity and liver disease

The commonly used food additive monosodium glutamate (MSG) has been linked to obesity and disorders associated with the metabolic syndrome including progressive liver disease.

28 May 2014

WHO member states recognize psoriasis as chronic, non-communicable disease

At the 67th World Health Assembly, the WHO member states adopted a resolution on psoriasis, recognizing it as "a chronic, non-communicable, painful, disfiguring, and disabling disease for which there is no cure."

27 May 2014

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.

19 May 2014

Melbourne researchers find link between necroptosis and inflammatory disease

A team of Melbourne researchers has shown a recently discovered type of cell death called necroptosis could be the underlying cause of inflammatory disease.

13 May 2014

Exposure to microgravity can simulate aging for immune cells

Telling someone to "act your age" is another way of asking him or her to behave better. Age, however, does not always bring improvements.

23 Apr 2014

Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

Interleukin Genetics, Inc. today announced it has received conditional approval from the New York State Department of Health to offer, process and report the results of the PerioPredict™ Genetic Risk Test for periodontal disease.

22 Apr 2014

LSTM researchers to conduct extensive research on HIV and schistosomiasis coinfection in African children

Researchers from LSTM have called for more research to be carried out into HIV and schistosomiasis coinfection in children in sub-Saharan Africa.

18 Apr 2014

Research on HIV and schistosomiasis coinfection in sub-Saharan Africa children

Paper shows that more work is needed to fully understand the consequences of coinfection. Researchers from LSTM have called for more research to be carried out into HIV and schistosomiasis coinfection in children in sub-Saharan Africa.

17 Apr 2014

Researchers uncover mechanism that may help explain severe forms of schistosomiasis

Researchers at the Sackler School of Graduate Biomedical Sciences at Tufts and Tufts University School of Medicine (TUSM) have uncovered a mechanism that may help explain the severe forms of schistosomiasis, or snail fever, which is caused by schistosome worms and is one of the most prevalent parasitic diseases in the world. The study in mice, published online in The Journal of Immunology, may also offer targets for intervention and amelioration of the disease.

17 Apr 2014

Loyola offers patients the most advanced PET/CT scanner

Loyola University Medical Center is now offering patients the most advanced PET/CT scanner on the market. The state-of-the-art system is improving the diagnosis and treatment of cancer, heart disease, epilepsy, Alzheimer's disease and other conditions.

11 Apr 2014

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.

8 Apr 2014

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.

7 Apr 2014

UPCI/MWRI researchers to present results of immune gene profile exploring endometriosis and cancer

Some women with endometriosis, a chronic inflammatory disease, are predisposed to ovarian cancer, and a genetic screening might someday help reveal which women are most at risk, according to a University of Pittsburgh Cancer Institute (UPCI) study, in partnership with Magee-Womens Research Institute (MWRI).

7 Apr 2014

Transplant drugs may help defeat HIV

Drugs that are currently given to prevent organ rejection in patients who have received a transplant may offer a new approach to curing HIV, say researchers.

3 Apr 2014

Novel proteins may lead to new ways to combat venereal disease

Researchers at Oregon State University have discovered novel proteins in, or on the surface of the bacteria that causes gonorrhea, which offer a promising new avenue of attack against a venereal disease that is showing increased resistance to the antibiotics used to treat it.

1 Apr 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014